Listen to this article

00:00
00:00

Reckitt Benckiser confirmed it would acquire US nutrition company Mead Johnson for $90 per share in cash, as the pharmaceuticals group announced 3 per cent drop in operating profit last year.

The UK-based maker of Nurofen painkillers and Durex condoms said the total value of the transaction, which it expects to complete by September, was $17.9bn including Mead Johnson’s net debt, valuing the US company’s equity at $16.6bn.

News of the planned deal first broke last week, when Reckitt confirmed it was in advanced talks with Mead Johnson to pay $90 a share.

Reckitt chief executive Rakesh Kapoor said: “The acquisition of Mead Johnson is a significant step forward in RB’s journey as a leader in consumer health.”

He added:

Mead Johnson’s geographic footprint significantly strengthens our position in developing markets, which will account for approximately 40% of the combined group’s sales, with China becoming our second largest Powermarket.

Confirmation of the deal came as Reckitt released its full-year results for 2016, showing a 3 per cent fall in operating profits at constant exchange rates and without adjusting for exceptional items. With currency effects, operating profit rose 8 per cent to £2.4bn.

Net income fell 5 per cent at constant exchange rates and rose 5 per cent in actual terms, taking currency fluctuations into account, to £1.8bn. Net revenue rose to £9.9bn for the year, up 11 per cent in actual terms and up 2 per cent at constant exchange rates.

“In 2017, we expect macro conditions to remain challenging, and for a number of existing headwinds to persist in the first half. We are targeting LFL net revenue growth of 3 per cent. For operating margin, we reiterate our medium term target of moderate margin expansion,” said Mr Kapoor.

Copyright The Financial Times Limited 2017. All rights reserved.
myFT

Follow the topics mentioned in this article

Follow the authors of this article

Comments have not been enabled for this article.